Polydex Pharma Revenue, Profits - POLXF Quarterly Income Statement

Add to My Stocks
$0.98 $0 (0%) POLXF stock closing price Sep 18, 2018 (Closing)

POLXF stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Polydex Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement for POLXF which shows a YOY revenue growth of 12.98% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. Along with Polydex Pharma assets and Polydex Pharma free cash flow, Polydex Pharma profits as shown in profit and loss statement give key insights about the business. The net profit for 2019 Q1 is $- and the 2019 Q1 revenue is $1.48M.

View and download details of revenue and profits for Polydex Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Feb - Jan2019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q4
Polydex Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)--1.09M--1.57M1.03M1.15M1.05M1.12M
Polydex Pharma Gross Profit
Research & Development Expense----------
Selling General & Admin Expense----------
Income Before Depreciation Depletion Amortization--0.03M--------0.04M
Depreciation Depletion Amortization----------
Non Operating Income----0.15M-----0.17M-0.44M
Interest Expense----------
Polydex Pharma Pretax Income
Provision for Income Taxes----------0.21M
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations----0.02M------
Extraordinary Items & Discontinued Operations----------
Polydex Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS3.48M3.33M3.49M3.4M3.51M3.41M3.52M3.52M3.55M3.6M
Average Shares used to compute Basic EPS3.42M3.33M3.4M3.4M3.4M3.41M3.38M3.38M3.38M3.6M
Income Before Nonrecurring Items----0.02M------
Income from Nonrecurring Items----------
Polydex Pharma Earnings Per Share Basic Net
Polydex Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.030.030.07-
Preferred Dividends Acc Pd--0.01M--------
Dividends Common0.000.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Polydex Pharma stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $1.48M for this quarter of 2019 Q1. Our Polydex Pharma revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $- for Polydex Pharma for 2019 Q1. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The POLXF financials along with Polydex Pharma historical stock prices provide a lot of details about the firm.

Polydex Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield